2018
CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
Gisslén M, Heslegrave A, Veleva E, Yilmaz A, Andersson LM, Hagberg L, Spudich S, Fuchs D, Price RW, Zetterberg H. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurology Neuroimmunology & Neuroinflammation 2018, 6: e512. PMID: 30568991, PMCID: PMC6278890, DOI: 10.1212/nxi.0000000000000512.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-negative controlsMicroglial activationNeuronal injuryCSF concentrationsUntreated HIV-1-infected patientsHIV-1 disease severityHIV-1-infected adultsMacrophage/microglial activationHIV-1-infected patientsRetrospective cross-sectional studyUntreated HIV-1 infectionCNS immune activationCSF sTREM2 levelsSuppressive antiretroviral treatmentT-cell countsMicroglial activation markersT cell lossLevels of CSFNeurofilament light proteinCross-sectional studyCSF sTREM2STREM2 levelsAntiretroviral treatmentActivation markers
2009
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. PLOS ONE 2009, 4: e6877. PMID: 19721718, PMCID: PMC2731205, DOI: 10.1371/journal.pone.0006877.Peer-Reviewed Original ResearchConceptsHIV-1 infectionRaltegravir concentrationsCerebrospinal fluidTreatment-experienced HIV-1-infected patientsSystemic HIV-1 infectionHIV-1-infected patientsHIV-1-infected individualsIntegrase inhibitorsCentral nervous system penetrationAntiretroviral treatment regimensDrug entryPlasma albumin ratioCerebrospinal fluid concentrationsBlood-CSF barrierCSF albumin concentrationPlasma raltegravir concentrationsTreatment regimensAlbumin ratioDrug classesCSF specimensHIV-1CSF samplesAlbumin concentrationFluid concentrationsLiquid chromatography-tandem mass spectrometry
2008
Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy
Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 47: 168-173. PMID: 17971711, PMCID: PMC2628632, DOI: 10.1097/qai.0b013e31815ace97.Peer-Reviewed Original ResearchConceptsCSF neopterin levelsHIV-1-infected patientsHIV-1-infected individualsCSF neopterin concentrationsCSF viral loadIntrathecal immune activationAntiretroviral therapyHIV-1 RNACopies/mLNeopterin levelsViral loadNeopterin concentrationsImmune activationCSF HIV-1 RNA loadMost HIV-1-infected individualsPlasma HIV-1 RNA levelsCerebrospinal fluid (CSF) neopterin levelsQuantitative HIV-1 RNAHIV-1 RNA levelsHIV-1 RNA loadCell-mediated immune responsesHIV-1 RNA quantificationHIV-1 concentrationsStable antiretroviral therapySuppressive antiretroviral therapy
2006
Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia
Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia. The Journal Of Infectious Diseases 2006, 194: 926-930. PMID: 16960780, DOI: 10.1086/507312.Peer-Reviewed Original ResearchConceptsT-cell countsX4-tropic virusesCXCR4-tropic virusesDetectable viremiaCell countUntreated human immunodeficiency virusHIV-1-infected patientsClinic-based cohortTreatment-naive participantsT-cell depletionHuman immunodeficiency virusViral coreceptor usageCXCR4 tropismSalvage therapySignificant CD4Advanced immunodeficiencyImmunodeficiency virusCell depletionCoreceptor usageCCR5 inhibitorsLow pretreatmentViremiaCD4VirusPatients